SOLUTRANS
26.10.2021 08:02:12 CEST | Business Wire | Press release
SOLUTRANS , the global hub for heavy and light commercial vehicles, will hold its 16th edition from 16 to 20 November 2021 in Lyon Eurexpo (France). Nearly 60,000 professionals, 1,000 exhibitors and brands are expected to attend this international event focusing on economic recovery and innovation, certified by the OICA (International Organization of Motor Vehicle Manufacturers).
This edition will showcase two major additions. Firstly, a "SOLUTRANS 4.0" hall dedicated to innovation for transport professionals. Secondly, the chance for professionals from all over the world to take part in the show remotely via the SOLUTRANS DIGITAL SHOW.
HGV manufacturers will be in attendance
The leading HGV manufacturers, such as DAF, IVECO, MAN, Mercedes, Renault Trucks, SCANIA and VOLVO will be exhibiting at SOLUTRANS. The largest bodywork manufacturers, vehicle fitters and service companies will also be present, as well as new names in the sector such as FORD TRUCKS, IRIZAR and VOLTA TRUCKS, who will be taking part for the first time in France.
SOLUTRANS 4.0, the hall of new technologies
This hall will present disruptive innovations and new names in the sector in all areas, from engineering to industry as well as IT solutions.
The objective of SOLUTRANS 4.0 is to foster the implementation of new solutions to optimize activity and overcome the challenges in the sector: energy transition, artificial intelligence, cybersecurity, recycling, etc.
Innovation gets the green light at SOLUTRANS !
All the innovations will be presented during the various award ceremonies that will take place during the trade show. The I-nnovation Awards have been further enriched this year and include a new prize: the "Digital AWARD". Also, for the fourth consecutive edition, SOLUTRANS will host the International Awards: ITOY, IVOTY, IPUA and TRUCK INNOVATION AWARD. These awards, recognized by the industry as a whole, reward the excellence of manufacturers and showcase the trends in the industrial and urban vehicle sector.
The theme of innovation will also be highlighted during the event via a broad range of conferences covering a variety of topics that respond to the challenges of the sector.
Finally, SOLUTRANS, in partnership with TotalEnergies, will be offering a new, completely redesigned and larger testing area to meet the needs of visitors and manufacturers of heavy and light commercial vehicles. The track has also been extended and re-designed with a 25 km semi-urban route to allow professionals to test the vehicles around the park.
SOLUTRANS DIGITAL SHOW: unlimited online access to the trade show
The SOLUTRANS DIGITAL SHOW, the virtual edition of the physical exhibition, will offer registered visitors, wherever they are located in the world, an interactive space where they can visit exhibitors' stands, contact their representatives and discover their new products… it’s all just click away! Two weeks before the actual trade show, registered visitors will be able to start making appointments with exhibitors and take advantage of the three additional days of opening to consult an exhibitor's offer online, thus giving them a chance to contact businesses that they wouldn’t have had time to meet during the physical edition of the trade show. They will also have access to conferences and other events, which will be broadcast live.
Discover the whole program of the SOLUTRANS 2021 trade show on solutrans.eu
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005031/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom